Imperial College London

ProfessorStephenBrett

Faculty of MedicineDepartment of Surgery & Cancer

Professor of Critical Care
 
 
 
//

Contact

 

+44 (0)20 3313 4521stephen.brett Website

 
 
//

Location

 

Hammersmith House 570Hammersmith HospitalHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Lipman:2019,
author = {Lipman, J and Brett, SJ and De, Waele J and Osbert, Cota M and Davis, J and Finfer, S and Glass, P and Knowles, S and McGuiness, S and Myburgh, J and Paterson, D and Peake, S and Rajbhandari, D and Rhodes, A and Roberts, J and Shirwadkar, C and Starr, T and Taylor, C and Billott, L and Joel, D},
journal = {Critical Care and Resuscitation},
title = {A protocol for a Phase 3 multicentre randomised controlled trial of continuous versus intermittent beta-lactam antibiotic infusion in critically ill patients with sepsis: the BLING III trial},
year = {2019}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - ackground and rationale:Beta-lactam antibiotics displaya time-dependent mechanism of action with evidence suggesting improved outcomes when administering these drugs via continuous infusion as compared with standard intermittent infusion. However, there is no phase 3randomised controlled trial (RCT) evidence to support one method of administration over another in critically ill patients with sepsis.Design and setting:BLING III is a prospective, multicentre, open, phase 3RCT to compare continuous infusion with standard intermittent infusion of beta-lactam antibiotics in critically ill patients with sepsis.The study will be conducted in approximately 70 Intensive Care Units (ICUs) in Australia, New Zealand, United Kingdom, Belgium and selected other countries from 2018 to 2021.Participants and interventions: BLING IIIwill recruit 7000 critically illpatients with sepsis being treated with one of two beta-lactam antibiotics (piperacillin-tazobactam ormeropenem) to receive the beta-lactam antibiotic by either continuous or intermittentinfusion.Main outcome measures: The primary outcome isall-cause mortality within 90 days after randomisation. Secondary outcomes are clinical cure at Day 14 post randomisation, new acquisition, colonisation or infection with a multi-resistant organism or Clostridium difficilediarrhoea up to 14 days post randomisation, all-cause ICU mortality and all-cause hospital mortality. Tertiary outcomes are ICU length of stay, hospital length of stay and duration of mechanical ventilation andduration of renal replacement therapy up to 90 days after randomisation.Results and conclusions: The BLING IIIstudy will compare the effect on 90-day mortality of beta-lactam antibiotics administered via continuous vs. intermittent infusion in 7000 critically ill patients with sepsis.
AU - Lipman,J
AU - Brett,SJ
AU - De,Waele J
AU - Osbert,Cota M
AU - Davis,J
AU - Finfer,S
AU - Glass,P
AU - Knowles,S
AU - McGuiness,S
AU - Myburgh,J
AU - Paterson,D
AU - Peake,S
AU - Rajbhandari,D
AU - Rhodes,A
AU - Roberts,J
AU - Shirwadkar,C
AU - Starr,T
AU - Taylor,C
AU - Billott,L
AU - Joel,D
PY - 2019///
SN - 1441-2772
TI - A protocol for a Phase 3 multicentre randomised controlled trial of continuous versus intermittent beta-lactam antibiotic infusion in critically ill patients with sepsis: the BLING III trial
T2 - Critical Care and Resuscitation
ER -